About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

11/04/2026 | Bruno Lauterjung | Digital Health News

https://saudedigitalnews.com.br/04/11/2026/oracle-aposta-em-inteligencia-artificial-para-reduzir-barreiras-no-atendimento-e-na-pesquisa-medica/ 

Artificial intelligence can transform the way hospitals, laboratories, and healthcare professionals share information, monitor patients, and develop treatments. That was the main message from Larry Ellison, founder and CTO of Oracle, during Oracle AI World 2026, held last week in Las Vegas, United States. The executive presented a new generation of applications for the healthcare sector, designed to integrate clinical and administrative processes with AI capabilities.

Under the theme “The New Oracle Health Application Suite and the Age of AI,” Ellison outlined the company’s strategy to expand the reach of Oracle Health. The goal is to build a platform capable of connecting hospitals, clinics, laboratories, diagnostic imaging centers, emergency services, and home care, thereby reducing the fragmentation of the systems used by these institutions.

According to the executive, Oracle chose healthcare as the starting point for developing industry-specific applications based on artificial intelligence because it considers this one of the most complex markets in the world. In addition to the diversity of medical specialties, the sector must keep pace with scientific advancements and meet regulatory requirements that vary from country to country.

One of the key proposed changes involves how professionals interact with hospital systems. Instead of navigating through different screens to locate test results, review medical records, or enter information, doctors will be able to use natural language commands to access data and perform specific tasks.

Ellison illustrated…

11/04/2026 | WHO

https://www.who.int/news/item/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances 

Expert groups convened by the World Health Organization (WHO) have recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC). The recommendation marks the first time vaccines specifically designed to protect against Bundibugyo virus, the virus responsible for the current outbreak, will be evaluated during an outbreak of the disease.

The two vaccine candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. WHO’s independent Technical Advisory Group on Candidate Vaccines Prioritization recommended both for further clinical evaluation this week, based on available preclinical and early clinical evidence. The companies were informed on Monday. The vaccine candidates will enter the trial following national approvals.

“The fact that these vaccines are ready to enter clinical trials is a testament to the power of science and partnership,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “I thank the scientists, health workers and partners in the DRC and around the world who have brought us to this point, and especially the people taking part in the trial. Their participation will generate vital evidence that could help save lives. Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control.”

The Institut National de Recherche Biomédicale, the DRC's national public health and biomedical research institute is leading the vaccines trial, with support from the University of Antwerp, Belgium, WHO, Epicentre, Médecins…

11/04/2026 | Aaron Tallent | Oncology News Central

https://www.oncologynewscentral.com/oncology/private-sector-helps-improve-clinical-trial-enrollment-in-community-oncology-practices 

Lack of infrastructure, administrative burden cited as biggest barriers.

Administrative burdens, infrastructure challenges, and logistical issues are just some of the obstacles many community cancer practices face in offering clinical trials. To help overcome them, more companies are using technological advances to take some of the non-patient-facing work off these practices’ plates.

“Our goal is to lower the threshold for our practices to participate in research, and so what we do is take away a lot of those–we call them back-office type operations–the budgeting and contracting, the regulatory, the quality team, the finance team,” said Ian Flinn, MD, PhD, chief scientific officer for OneOncology, a practice-management company based in Nashville, Tennessee. “It allows them to concentrate on the patient-facing aspect.”

Johnson & Johnson’s 2026 Oncology Care Index, which surveyed more than 200 community oncologists and practice administrators, reported that while a majority agreed that their patients’ ability to access clinical trials has improved compared with two years ago, six in 10 community oncologists and half of practice administrators surveyed said their practice offers limited clinical trial options. The most-cited barriers to enrolling more patients were lack of infrastructure and administrative burden.

Dr. Flinn leads OneR, OneOncology’s research network with 15 community practice systems. OneR helps practices offer more clinical trials through support services in areas that include contracts and budgets,…

11/04/2026 | AFP

https://www.afp.com/de/node/3851262 

The World Health Organization on Wednesday approved clinical trials for two new Ebola vaccines, as doctors fight to control an outbreak in Africa that has killed more than 5,300 people.

"Last month, a vaccine trial began using the Ervebo vaccine, which is approved for Ebola virus, but not for Bundibugyo virus" ravaging the Democratic Republic of Congo, WHO chief Tedros Adhanom Ghebreyesus told reporters.

"Today, WHO expert groups are recommending adding two vaccine candidates to the trial" he added.

Those two -- ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469 -- were developed specifically for the Bundibugyo virus, he explained.

The DRC's National Institute for Biomedical Research is leading the trial, backed by partners including WHO, said Tedros.

"Vaccines are powerful tools, but they are not substitutes for the proven measures that can save lives now: early care, contact tracing, isolation, safe and dignified burials and trusted engagement with communities," he added.

On Monday, the Africa Centres for Disease Control and Prevention (Africa CDC) said Africa's ongoing Ebola epidemic had killed more than 5,300 people, the vast majority of them in the Democratic Republic of Congo.

A total of 10,444 cases have been confirmed, with a fatality rate of more than 50 percent, it added.

11/03/2026  |  Bree Foster  |  DDN

https://www.drugdiscoverynews.com/can-precision-psychiatry-overcome-the-challenges-of-drug-development-17620 

Biomarkers could help researchers identify patients most likely to respond to psychiatric drugs, but translating early promise into clinical success remains a challenge.

Psychiatric drug development has one of the lowest success rates of any therapeutic area. One analysis found that just 7.9 percent of psychiatric drug candidates entering clinical development ultimately received regulatory approval, compared with an average of 9.6 percent across all therapeutic areas.

One challenge is that psychiatric diagnoses can encompass patients with very different underlying biology. Two people with major depressive disorder (MDD), for example, may experience similar symptoms but have different biological processes contributing to their illness and respond differently to the same treatment.

Despite this, clinical trials typically group patients by diagnosis, relying heavily on symptom scales to assess whether an experimental drug works. However, if a treatment only benefits a subset of patients, its effects may be harder to detect across the whole trial population, potentially obscuring a benefit in those most likely to respond.

There is now a growing movement to incorporate biological markers to stratify patients, monitor treatment response, and improve clinical trial design. Alto Neuroscience is among the companies pursuing this approach, combining biological and cognitive measurements with machine learning to guide psychiatric drug development.

But can this approach improve the odds of success? In 2024, Alto's investigational drug ALTO-100 failed to meet the primary endpoint in a Phase 2b trial for MDD. The result…